The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2009

Filed:

Nov. 22, 2006
Applicants:

Loen M. Hansford, Toronto, CA;

Kristen M. Smith, Toronto, CA;

Alessandro Datti, Toronto, CA;

Freda M. Miller, Toronto, CA;

David R. Kaplan, Toronto, CA;

Inventors:

Loen M. Hansford, Toronto, CA;

Kristen M. Smith, Toronto, CA;

Alessandro Datti, Toronto, CA;

Freda M. Miller, Toronto, CA;

David R. Kaplan, Toronto, CA;

Assignee:

The Hospital for Sick Children, Toronto, Ontario, CA;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 5/08 (2006.01); C12Q 5/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are enriched preparations of neuroblastoma tumor initiating cells (NB TICs). The NB TICs are capable of self-renewal, initiating neuroblastoma tumor growth in vivo and are capable of being passaged in high frequency. These NB TICs have chromosomal abnormalities and are capable of giving rise to secondary tumor spheres. Methods are also disclosed for preparing the enriched preparations of NB TICs, such as from neuroblastoma tumor tissue and metastasized bone marrow. Also disclosed are methods of screening candidate substances to identify therapeutic agents for the treatment of neuroblastoma. Methods are also provided for screening a sample for neuroblastoma, as well as for screening a sample to identify the stage of neuroblastoma present. Kits are also provided for selecting appropriate anti-neuroblastoma compounds for a patient, and utilize isolated compositions of the patients' neuroblastoma tumor initiating cells. In this manner, a customized medicinal profile for the patient may be devised.


Find Patent Forward Citations

Loading…